Oscar Health (OSCR) Stock Forecast, Price Target & Predictions
OSCR Stock Forecast
Oscar Health stock forecast is as follows: an average price target of $9.67 (represents a -55.31% downside from OSCR’s last price of $21.64) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
OSCR Price Target
The average price target for Oscar Health (OSCR) is $9.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $4.00. This represents a potential -55.31% downside from OSCR's last price of $21.64.
OSCR Analyst Ratings
According to 3 Wall Street analysts, Oscar Health's rating consensus is 'Hold'. The analyst rating breakdown for OSCR stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Oscar Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | John Ransom | Raymond James | $20.00 | $13.76 | 45.35% | -7.58% |
| Nov 15, 2022 | Stephen Baxter | Wells Fargo | $4.00 | $2.89 | 38.41% | -81.52% |
| Nov 14, 2022 | - | Morgan Stanley | $5.00 | $2.95 | 69.49% | -76.89% |
| Sep 01, 2022 | - | Morgan Stanley | $9.00 | $6.04 | 48.88% | -58.41% |
| Jun 09, 2022 | - | Morgan Stanley | $12.00 | $5.22 | 129.89% | -44.55% |
The latest Oscar Health stock forecast, released on Mar 21, 2024 by John Ransom from Raymond James, set a price target of $20.00, which represents a 45.35% increase from the stock price at the time of the forecast ($13.76), and a -7.58% decrease from OSCR last price ($21.64).
Oscar Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $20.00 | $20.00 |
| Last Closing Price | $21.64 | $21.64 | $21.64 |
| Upside/Downside | -100.00% | -7.58% | -7.58% |
In the current month, the average price target of Oscar Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Oscar Health's last price of $21.64. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 06, 2023 | Bank of America Securities | - | Neutral | Upgrade |
| May 17, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Nov 15, 2022 | Wells Fargo | - | Overweight | Upgrade |
| Nov 14, 2022 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Sep 01, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 09, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Oscar Health's last stock rating was published by Bank of America Securities on Jun 06, 2023. The company Upgrade its OSCR rating from "null" to "Neutral".
Oscar Health Financial Forecast
Oscar Health Revenue Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.43B | - | - | $1.47B | $1.04B | - | - | $1.01B | $520.33M | $462.19M | $549.75M | $388.69M |
| Avg Forecast | $2.18B | $2.13B | $2.05B | $2.23B | $1.98B | $1.94B | $1.86B | $2.03B | $2.39B | $2.38B | $2.38B | $2.46B | $2.09B | $2.14B | $2.18B | $1.99B | $1.43B | $1.42B | $1.38B | $1.27B | $1.18B | $1.07B | $1.10B | $1.03B | $564.51M | $543.73M | $588.30M | $597.79M |
| High Forecast | $2.20B | $2.15B | $2.07B | $2.25B | $2.00B | $1.95B | $1.88B | $2.05B | $2.40B | $2.40B | $2.40B | $2.48B | $2.11B | $2.15B | $2.20B | $2.01B | $1.43B | $1.43B | $1.40B | $1.28B | $1.19B | $1.08B | $1.10B | $1.04B | $573.00M | $551.91M | $597.15M | $606.79M |
| Low Forecast | $2.17B | $2.12B | $2.04B | $2.22B | $1.97B | $1.92B | $1.85B | $2.02B | $2.37B | $2.36B | $2.37B | $2.45B | $2.08B | $2.12B | $2.17B | $1.98B | $1.42B | $1.42B | $1.38B | $1.26B | $1.17B | $1.06B | $1.09B | $1.02B | $558.74M | $538.18M | $582.29M | $591.69M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - | - | 1.15% | 0.88% | - | - | 0.98% | 0.92% | 0.85% | 0.93% | 0.65% |
Oscar Health's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.99B, with a low forecast of $1.98B, and a high forecast of $2.01B. OSCR's average Quarter revenue forecast represents a 39.05% increase compared to the company's last Quarter revenue of $1.43B (Dec 23).
Oscar Health EBITDA Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-145.48M | - | - | $-25.36M | $-216.89M | - | - | $-65.61M | $-194.67M | $-209.30M | $-68.66M | $-79.31M |
| Avg Forecast | $-697.12M | $-681.13M | $-655.85M | $-714.72M | $-634.42M | $-619.70M | $-596.35M | $-650.09M | $-763.16M | $-760.15M | $-762.41M | $-787.64M | $-668.63M | $-683.29M | $-698.84M | $-46.51M | $-335.70M | $-100.64M | $-104.30M | $-42.29M | $-265.38M | $-107.63M | $-94.81M | $-38.44M | $-209.79M | $-115.11M | $-86.20M | $-64.26M |
| High Forecast | $-692.67M | $-676.77M | $-651.66M | $-710.15M | $-630.36M | $-615.74M | $-592.53M | $-645.94M | $-758.28M | $-755.29M | $-757.53M | $-782.60M | $-664.36M | $-678.92M | $-694.37M | $-37.21M | $-268.56M | $-80.51M | $-83.44M | $-33.83M | $-212.30M | $-86.11M | $-75.85M | $-30.75M | $-167.83M | $-92.09M | $-68.96M | $-51.41M |
| Low Forecast | $-702.83M | $-686.70M | $-661.22M | $-720.57M | $-639.61M | $-624.77M | $-601.23M | $-655.41M | $-769.40M | $-766.37M | $-768.64M | $-794.08M | $-674.10M | $-688.88M | $-704.56M | $-55.82M | $-402.85M | $-120.76M | $-125.16M | $-50.74M | $-318.45M | $-129.16M | $-113.78M | $-46.13M | $-251.74M | $-138.14M | $-103.43M | $-77.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.43% | - | - | 0.60% | 0.82% | - | - | 1.71% | 0.93% | 1.82% | 0.80% | 1.23% |
undefined analysts predict OSCR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Oscar Health's previous annual EBITDA (undefined) of $NaN.
Oscar Health Net Income Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-150.03M | - | - | $-39.63M | $-226.56M | - | - | $-77.32M | $-197.74M | $-212.75M | $-73.07M | $-87.37M |
| Avg Forecast | $-14.69M | $35.26M | $85.20M | $155.71M | $-20.57M | $26.44M | $76.39M | $146.90M | $-107.24M | $-7.34M | $91.08M | $162.57M | $-162.76M | $-42.89M | $57.58M | $-53.27M | $-343.04M | $-102.29M | $-110.99M | $-48.43M | $-271.18M | $-109.40M | $-100.90M | $-44.03M | $-214.37M | $-117.01M | $-91.72M | $-70.80M |
| High Forecast | $-14.57M | $35.63M | $86.11M | $157.37M | $-20.39M | $26.72M | $77.20M | $148.46M | $-106.35M | $-7.28M | $92.05M | $164.30M | $-161.41M | $-42.54M | $58.20M | $-42.62M | $-274.44M | $-81.83M | $-88.79M | $-38.75M | $-216.94M | $-87.52M | $-80.72M | $-35.22M | $-171.50M | $-93.61M | $-73.38M | $-56.64M |
| Low Forecast | $-14.85M | $34.96M | $84.49M | $154.42M | $-20.78M | $26.22M | $75.75M | $145.68M | $-108.38M | $-7.42M | $90.32M | $161.21M | $-164.49M | $-43.35M | $57.11M | $-63.93M | $-411.65M | $-122.75M | $-133.18M | $-58.12M | $-325.42M | $-131.28M | $-121.08M | $-52.83M | $-257.25M | $-140.41M | $-110.07M | $-84.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.44% | - | - | 0.82% | 0.84% | - | - | 1.76% | 0.92% | 1.82% | 0.80% | 1.23% |
Oscar Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OSCR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Oscar Health SG&A Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $85.61M | - | - | $102.15M | $75.81M | - | - | $74.66M | $89.34M | $61.27M | $50.91M | $63.06M |
| Avg Forecast | $328.39M | $320.85M | $308.95M | $336.68M | $298.85M | $291.92M | $280.92M | $306.23M | $359.49M | $358.08M | $359.14M | $371.02M | $314.97M | $321.87M | $329.20M | $52.93M | $154.06M | $29.46M | $77.33M | $48.12M | $121.79M | $31.51M | $70.30M | $43.74M | $96.28M | $33.70M | $63.91M | $51.10M |
| High Forecast | $331.08M | $323.48M | $311.48M | $339.43M | $301.30M | $294.31M | $283.21M | $308.74M | $362.44M | $361.01M | $362.08M | $374.06M | $317.54M | $324.51M | $331.89M | $63.51M | $184.88M | $35.35M | $92.80M | $57.74M | $146.15M | $37.81M | $84.36M | $52.49M | $115.53M | $40.44M | $76.69M | $61.32M |
| Low Forecast | $326.29M | $318.80M | $306.97M | $334.52M | $296.94M | $290.05M | $279.12M | $304.28M | $357.20M | $355.79M | $356.84M | $368.65M | $312.95M | $319.81M | $327.09M | $42.34M | $123.25M | $23.57M | $61.86M | $38.49M | $97.43M | $25.21M | $56.24M | $34.99M | $77.02M | $26.96M | $51.13M | $40.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.56% | - | - | 2.12% | 0.62% | - | - | 1.71% | 0.93% | 1.82% | 0.80% | 1.23% |
Oscar Health's average Quarter SG&A projection for Mar 24 is $52.93M, based on 2 Wall Street analysts, with a range of $42.34M to $63.51M. The forecast indicates a -38.17% fall compared to OSCR last annual SG&A of $85.61M (Dec 23).
Oscar Health EPS Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.66 | - | - | $-0.18 | $-1.05 | - | - | $-0.37 | $-0.94 | $-1.02 | $-0.35 | $-0.98 |
| Avg Forecast | $-0.05 | $0.12 | $0.29 | $0.53 | $-0.07 | $0.09 | $0.26 | $0.50 | $-0.36 | $-0.03 | $0.31 | $0.55 | $-0.55 | $-0.15 | $0.20 | $0.27 | $-0.72 | $-0.47 | $-0.22 | $-0.06 | $-1.14 | $-0.72 | $-0.48 | $-0.21 | $-0.98 | $-0.73 | $-0.47 | $-0.53 |
| High Forecast | $-0.05 | $0.12 | $0.29 | $0.54 | $-0.07 | $0.09 | $0.26 | $0.51 | $-0.36 | $-0.02 | $0.31 | $0.56 | $-0.55 | $-0.14 | $0.20 | $0.28 | $-0.72 | $-0.47 | $-0.22 | $-0.06 | $-1.13 | $-0.71 | $-0.47 | $-0.21 | $-0.97 | $-0.72 | $-0.46 | $-0.53 |
| Low Forecast | $-0.05 | $0.12 | $0.29 | $0.53 | $-0.07 | $0.09 | $0.26 | $0.50 | $-0.37 | $-0.03 | $0.31 | $0.55 | $-0.56 | $-0.15 | $0.19 | $0.25 | $-0.73 | $-0.48 | $-0.22 | $-0.06 | $-1.15 | $-0.73 | $-0.48 | $-0.22 | $-1.00 | $-0.74 | $-0.48 | $-0.54 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | - | - | 2.97% | 0.92% | - | - | 1.73% | 0.96% | 1.40% | 0.75% | 1.83% |
According to undefined Wall Street analysts, Oscar Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OSCR previous annual EPS of $NaN (undefined).
Oscar Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BHG | NeueHealth | $16.35 | $7.68K | 46872.48% | Hold |
| CLOV | Clover Health Investments | $0.82 | $1.80 | 119.51% | Hold |
| CVS | CVS Health | $55.82 | $109.15 | 95.54% | Buy |
| HUM | Humana | $335.59 | $508.17 | 51.43% | Buy |
| ALHC | Alignment Healthcare | $6.83 | $9.00 | 31.77% | Buy |
| CNC | Centene | $77.79 | $93.53 | 20.23% | Buy |
| UNH | UnitedHealth Group | $512.81 | $554.32 | 8.09% | Buy |
| ELV | Elevance Health | $539.18 | $548.90 | 1.80% | Buy |
| MOH | Molina Healthcare | $354.60 | $345.00 | -2.71% | Buy |
| CI | Cigna | $348.39 | $311.57 | -10.57% | Buy |
| OSCR | Oscar Health | $21.64 | $9.67 | -55.31% | Hold |
OSCR Forecast FAQ
Is Oscar Health a good buy?
No, according to 3 Wall Street analysts, Oscar Health (OSCR) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of OSCR's total ratings.
What is OSCR's price target?
Oscar Health (OSCR) average price target is $9.67 with a range of $4 to $20, implying a -55.31% from its last price of $21.64. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Oscar Health stock go up soon?
According to Wall Street analysts' prediction for OSCR stock, the company can go down by -55.31% (from the last price of $21.64 to the average price target of $9.67), down by -7.58% based on the highest stock price target, and down by -81.52% based on the lowest stock price target.
Can Oscar Health stock reach $30?
OSCR's average twelve months analyst stock price target of $9.67 does not support the claim that Oscar Health can reach $30 in the near future.
What are Oscar Health's analysts' financial forecasts?
Oscar Health's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $7.82B (high $7.88B, low $7.77B), average EBITDA is $-2.501B (high $-2.485B, low $-2.521B), average net income is $229.16M (high $231.99M, low $226.87M), average SG&A $1.18B (high $1.19B, low $1.17B), and average EPS is $0.78 (high $0.79, low $0.772). OSCR's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $8.59B (high $8.66B, low $8.54B), average EBITDA is $-2.749B (high $-2.731B, low $-2.771B), average net income is $261.48M (high $264.54M, low $259.02M), average SG&A $1.29B (high $1.31B, low $1.29B), and average EPS is $0.89 (high $0.9, low $0.882).
Did the OSCR's actual financial results beat the analysts' financial forecasts?
Based on Oscar Health's last annual report (Dec 2023), the company's revenue was $5.86B, beating the average analysts forecast of $5.5B by 6.50%. Apple's EBITDA was $-236M, missing the average prediction of $-583M by -59.58%. The company's net income was $-271M, missing the average estimation of $-605M by -55.23%. Apple's SG&A was $339.72M, beating the average forecast of $308.97M by 9.95%. Lastly, the company's EPS was $-1.22, missing the average prediction of $-1.477 by -17.40%. In terms of the last quarterly report (Dec 2023), Oscar Health's revenue was $1.43B, beating the average analysts' forecast of $1.43B by 0.35%. The company's EBITDA was $-145M, missing the average prediction of $-336M by -56.67%. Oscar Health's net income was $-150M, missing the average estimation of $-343M by -56.27%. The company's SG&A was $85.61M, missing the average forecast of $154.06M by -44.43%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-0.723 by -8.65%